Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M60.8Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-2.6
Enterprise Value $M37.8EPS (TTM) $-0.1Operating Margin %--Piotroski F-Score1
P/E(ttm)--Beneish M-Score-4.1Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %-4.5Quick Ratio7.7Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %-13.7Current Ratio7.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-54.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-72.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M213ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RNN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RNNKen Fisher 2014-09-30 Sold Out $0.662 - $0.875
($0.75)
$ 0.29-61%Sold Out0
RNNKen Fisher 2014-06-30 Buy $0.79 - $1.28
($0.95)
$ 0.29-69%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RNN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


RNN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Jeong Tae HeumCFO 2015-01-12Sell317,272$0.91-68.13view
Ahn Chang HoDirector 2015-01-12Sell314,656$0.91-68.13view
Ahn Chang HoDirector 2014-06-12Sell136,193$0.99-70.71view
Jeong Tae HeumCFO 2013-09-09Sell71,139$0.46-36.96view
Kivel RichardDirector 2011-10-03Buy2,500$1.04-72.12view
Brandt Peter C.Director 2011-09-09Buy125,000$1.17-75.21view
Brandt Peter C.Director 2011-09-07Buy25,000$0.96-69.79view
Ahn Chang HoChairman & CEO, 10% Owner 2011-05-18Buy1,008,078$1.31-77.86view
Ahn Chang HoChairman & CEO, 10% Owner 2011-04-01Buy320,846$1.22-76.23view
McIntosh David MDirector 2009-07-30Buy5,600$0.8-63.75view

Quarterly/Annual Reports about RNN:

News about RNN:

Articles On GuruFocus.com
Weekly CEO Buys Highlight: RNN, IIG, FSC, GEO, DAN May 21 2011 
Weekly CEO Buys Highlight: GBDC, EXL, RNN, KYN, CMTL Apr 09 2011 

More From Other Websites
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual... May 23 2016
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual... May 23 2016
Rexahn Drugs Deal a Death Blow to Solid Tumor Cancer May 19 2016
REXAHN PHARMACEUTICALS, INC. Financials May 17 2016
Rexahn reports 1Q loss May 09 2016
Rexahn reports 1Q loss May 09 2016
Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update May 09 2016
Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update May 09 2016
REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 06 2016
ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report Apr 28 2016
Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American... Apr 20 2016
Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American... Apr 20 2016
Rexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual... Apr 13 2016
Rexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual... Apr 13 2016
Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral... Mar 29 2016
Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral... Mar 29 2016
Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative... Mar 24 2016
Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative... Mar 24 2016
Rexahn reports 4Q loss Mar 14 2016
Rexahn reports 4Q loss Mar 14 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)